ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » AMGN Stock Price » AMGN Stock News

Amgen Inc. Share News

 Amgen Inc. (mm) Stock Price
AMGN Stock Price
 Amgen Inc. (mm) Stock Chart
AMGN Stock Chart
 Amgen Inc. (mm) Stock News
AMGN Stock News
 Amgen Inc. (mm) Company Information
AMGN Company Information
 Amgen Inc. (mm) Stock Trades
AMGN Stock Trades

Amgen Says Recent Sensipar Study Failed to Meet Primary Endpoint

By Mia Lamar Amgen Inc. (AMGN) said Friday that a study evaluating its Sensipar drug for effectiveness in reducing the risk of mortality and cardiovascular events in patients suffering from chronic kidney disease failed to meet its primary endpoint. Sensipar--which is marketed as Mimpara in Europe--was first approved in 2004 to treat thyroid problems in patients with kidney disease and cancer. The company recorded $808 million in global sales of the drug last year. Amgen said Friday it undertook the Phase 3 trial of Sensipar to discover whether the drug could positively impact the high rates of mortality and incidences like heart failure experienced by patients with chronic kidney disease that are receiving dialysis. Results, however, were not statistically significant, Amgen said. The company noted analyses from the study are ongoing and will be submitted for presentation at a major medical meeting later this year. Amgen, the biggest stand-alone biotechnology company, has been pursuing deals to bolster its research-and-development pipeline as sales growth slows for older drugs. Shares were recently off 26 cents to $68.84. Write to Mia Lamar at [email protected]

Stock News for Amgen Inc. (AMGN)
DateTimeHeadline
01/19/201717:29:35Amended Statement of Ownership (sc 13g/a)
01/17/201710:00:00deCODE Study Shows that Variants in the Sequence of the Genome...
01/17/201705:00:00deCODE Study Shows that Variants in the Sequence of the Genome...
01/13/201717:17:58Post-effective Amendment to an S-8 Filing (s-8 Pos)
01/13/201717:11:28Post-effective Amendment to an S-8 Filing (s-8 Pos)
01/13/201716:21:00Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech...
01/10/201716:12:00Study Results Published in the Journal of the American Medical...
01/09/201718:21:00Amgen Statement on January 9, 2017, U.S. District Court Decision
01/09/201706:12:09Current Report Filing (8-k)
01/09/201706:00:00Amgen And DaVita Enter Into New Sourcing And Supply Agreement
01/09/201704:00:00Amgen and Immatics Enter Strategic Collaboration to Develop Novel...
01/06/201714:29:00Sanofi Investors Count Cost of Praluent Ruling -- Update
01/06/201708:41:00Sanofi Investors Count Cost of Praluent Ruling
01/06/201703:02:00Sanofi Loses Patent Case -- WSJ
01/05/201721:34:00Court Grants Permanent Injunction For Infringement Of Amgen's...
01/05/201721:07:00Judge Rules Against Sanofi and Regeneron in Patent Case -- Update
01/05/201720:25:00Judge Rules Against Sanofi and Regeneron in Patent Case
01/04/201716:00:00Amgen To Present At The 35th Annual J.P. Morgan Healthcare Conference
12/22/201619:27:00Donald Trump's Pick for Health Secretary Traded Medical Stocks...
12/20/201616:20:00Amgen Announces 15 Percent Increase In 2017 First Quarter Dividend

Amgen Inc. and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US